DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS

细胞病理学诊断的辅助诊断

• 批准号: 2464426
• 负责人: A ABATI
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2464426
• 关键词: adolescence (12-20); biomarker; breast neoplasms; child (0-11); clinical research; cytodiagnosis; fine needle aspiration; human subject; human tissue; immunocytochemistry; lymphoma; melanoma; neoplasm /cancer diagnosis; tumor antigens

Immunocytochemistry has proved to be a valuable diagnostic adjunct to cytopathologic diagnosis. The Cytopathology Section is involved in several clinically-related research projects, many of which utilize fine needle aspiration (FNA) and immunocytochemistry to provide ancillary diagnostic information regarding expression of various tumor antigens, HLA antigens or other markers. A partial listing of such studies includes: (1) Evaluation of percent of tumor cells expressing CD22 and CD19 in FNA specimens as part of a clinical trial using monoclonal antibody therapy for refractory lymphomas; (2) Evaluation of expression of drug resistance marker P-glycoprotein prospectively by FNA in breast cancer patients treated with new combination chemotherapy; (3) Cytologic diagnosis and immunophenotyping of ocular lymphomas; (4) characterization and application of a novel murine monoclonal antibody for malignant melanoma, MART-1 with subsequent quantitation of MART-1 in FNAs from malignant melanoma patients for treatment with anti-MART-1 antibody; (5) morphologic and immunocytochemical evaluation of bone marrow and peripheral blood samples for the detection of malignant cells in patients with stage IV breast cancer; (6) cytologic and immunocytochemical analysis of anaplastic large cell lymphomas.

事实证明，免疫细胞化学是一个有价值的诊断 细胞病理学诊断。 细胞病理学部分参与 几个与临床相关的研究项目，其中许多利用了良好 针吸气（FNA）和免疫细胞化学以提供辅助 有关各种肿瘤抗原的表达HLA的诊断信息 抗原或其他标记。 此类研究的部分清单包括： （1）评估FNA中表达CD22和CD19的肿瘤细胞百分比 标本作为使用单克隆抗体治疗的临床试验的一部分 耐火淋巴瘤； （2）评估耐药性表达 FNA在乳腺癌患者中前瞻性标记P-糖蛋白 用新的组合化疗治疗； （3）细胞学诊断和 眼淋巴瘤的免疫表型； （4）表征和 新型鼠单克隆抗体用于恶性黑色素瘤， MART-1随后对FNA中的MART-1定量恶性肿瘤 黑色素瘤患者用抗MART-1抗体治疗； （5）形态学 以及骨髓和外周血的免疫细胞化学评估 检测IV期患者恶性细胞的样品 乳腺癌; （6）对变性的细胞学和免疫细胞化学分析 大细胞淋巴瘤。